Dyne Therapeutics Inc.

17.33-0.5500-3.08%Vol 618.98K1Y Perf -26.74%
Apr 20th, 2021 16:00 DELAYED
BID16.19 ASK17.58
Open17.76 Previous Close17.88
Pre-Market- After-Market17.33
 - -  - -%
Target Price
34.00 
Analyst Rating
— — 0.00
Potential %
96.19 
Finscreener Ranking
★★ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     60.24
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     60.26
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap891.84M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
20.36 
Earnings Date
3rd Jun 2021

Today's Price Range

16.9918.08

52W Range

13.5032.31

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
0.99%
1 Month
9.61%
3 Months
-18.41%
6 Months
1.40%
1 Year
-26.74%
3 Years
35.28%
5 Years
3.28%
10 Years
-

TickerPriceChg.Chg.%
DYN17.33-0.5500-3.08
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
31.50
31.80
0.03
0.03
-149.10
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
39.40
1.60
18.60
-23.60
-14.58
RevenueValueIndustryS&P 500US Markets
0.00
0.00
25.32
36.24
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.38-0.64-68.42
Q03 2020-0.88-2.01-128.41
Q04 2017-0.330.01103.03
Q03 20170.60-0.51-185.00
Q02 2017-0.22-0.83-277.27
Q01 2017-0.45-0.0393.33
Q04 2016-0.62-0.70-12.90
Q03 20160.070.01-85.71
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.60-33.33Negative
6/2021 QR-0.63-18.87Negative
12/2021 FY-2.59-14.10Negative
12/2022 FY-3.02-6.71Negative
Next Report Date3rd Jun 2021
Estimated EPS Next Report-0.60
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume618.98K
Shares Outstanding51.46M
Trades Count2.28K
Dollar Volume4.59M
Avg. Volume418.71K
Avg. Weekly Volume283.38K
Avg. Monthly Volume247.55K
Avg. Quarterly Volume465.71K

Dyne Therapeutics Inc. (NYSE: DYN) stock closed at 17.33 per share at the end of the most recent trading day (a -3.08% change compared to the prior day closing price) with a volume of 618.98K shares and market capitalization of 891.84M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Dyne Therapeutics Inc. CEO is Joshua T. Brumm.

The one-year performance of Dyne Therapeutics Inc. stock is -26.74%, while year-to-date (YTD) performance is -17.48%. DYN stock has a five-year performance of 3.28%. Its 52-week range is between 13.5 and 32.31, which gives DYN stock a 52-week price range ratio of 20.36%

Dyne Therapeutics Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 2.29, a price-to-sale (PS) ratio of -, a price to cashflow ratio of 3.50, a PEG ratio of 2.32, a ROA of -32.15%, a ROC of -9.19% and a ROE of -36.13%. The company’s profit margin is -14.58%, its EBITDA margin is 18.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Dyne Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.60 for the next earnings report. Dyne Therapeutics Inc.’s next earnings report date is 03rd Jun 2021.

The consensus rating of Wall Street analysts for Dyne Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Dyne Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Dyne Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Dyne Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.15, ATR14 : 1.35, CCI20 : 116.61, Chaikin Money Flow : 0.31, MACD : -0.75, Money Flow Index : 76.10, ROC : 15.13, RSI : 42.26, STOCH (14,3) : 95.73, STOCH RSI : 1.00, UO : 68.87, Williams %R : -4.27), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Dyne Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
2 (40.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
2 (40.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
1 (20.00 %)
Summary Rating---

Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.

CEO: Joshua T. Brumm

Telephone: +1 781 786-8230

Address: 830 Winter Street, Waltham 02451, MA, US

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

57%43%

Bearish Bullish

67%33%

News

Stocktwits